CRISPR/CRSP
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About CRISPR
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Ticker
CRSP
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Zug, Switzerland
Employees
407
Website
www.crisprtx.com
CRISPR Metrics
BasicAdvanced
$4.5B
Market cap
-
P/E ratio
-$2.72
EPS
1.79
Beta
-
Dividend rate
Price and volume
Market cap
$4.5B
Beta
1.79
Financial strength
Current ratio
17.813
Quick ratio
17.717
Long term debt to equity
10.506
Total debt to equity
11.273
Management effectiveness
Return on assets (TTM)
-7.97%
Return on equity (TTM)
-11.03%
Valuation
Price to revenue (TTM)
15.64
Price to book
2.16
Price to tangible book (TTM)
2.16
Price to free cash flow (TTM)
-25.13
Growth
Revenue change (TTM)
171.01%
Earnings per share change (TTM)
-59.38%
3-year revenue growth
527.25%
3-year earnings per share growth
-21.56%
What the Analysts think about CRISPR
Analyst Ratings
Majority rating from 29 analysts.
CRISPR Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$500K
-99.75%
Net income
-$117M
-230.46%
Profit margin
-23,300.00%
-52,601.13%
CRISPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.98
-$1.41
$1.10
-$1.43
-
Expected
-$2.12
-$1.95
-$0.07
-$1.33
-$1.51
Surprise
-53.72%
-27.72%
-1,622.98%
7.29%
-
CRISPR News
AllArticlesVideos
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
Seeking Alpha·3 weeks ago
The 'Undercovered' Dozen From June 1-6
Seeking Alpha·4 weeks ago
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CRISPR stock?
CRISPR (CRSP) has a market cap of $4.5B as of July 04, 2024.
What is the P/E ratio for CRISPR stock?
The price to earnings (P/E) ratio for CRISPR (CRSP) stock is 0 as of July 04, 2024.
Does CRISPR stock pay dividends?
No, CRISPR (CRSP) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next CRISPR dividend payment date?
CRISPR (CRSP) stock does not pay dividends to its shareholders.
What is the beta indicator for CRISPR?
CRISPR (CRSP) has a beta rating of 1.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell CRISPR stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.